Journal: Clinical Pharmacology and Therapeutics

Article Title: Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus

doi: 10.1002/cpt.3626

Figure Lengend Snippet: Associations between SGLT2i use and urolithiasis in different locations using conditional Cox regression models.

Article Snippet: Compared to SGLT2i users in TriNetX, those in the NHIRD were younger, had a higher proportion of males, and higher prevalence of hypertension, hyperlipidemia, CVD, gout, and urinary tract infections.

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies

doi: 10.3389/fphar.2023.1275060

Figure Lengend Snippet: Baseline characteristics of included studies.

Article Snippet: , USA , Optum , SGLT-2i , with PVD , 72.29±7.39 , , 18.6 , 44.3 , 7.5m , 28847.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review

doi: 10.3390/jcm13185408

Figure Lengend Snippet: Studies investigating the potential antiarrhythmic effects of SGLT2is on AF incidence.

Article Snippet: Zhou et al., 2022 [ ] , First Affiliated Hospital of Anhui Medical University (China) , Observational Retrospective Single-center Study , Patients with HF (n = 903), including 78 participants with AF and 825 participants without AF at baseline. , EMPA DAPA CANA , N/A , SGLT2i users experienced a lower prevalence of AF (8.4% vs. 12.1%, p < 0.001) and a lower risk of developing AF (OR 0.76, 95% CI: [0.70–0.85], p < 0.001) compared to non-SGLT2i users. The effect of SGLT2is on AF episodes was consistent irrespectively of age, gender, BMI, and eGFR..

Techniques: Modification, Biomarker Discovery

Journal: Journal of Clinical Medicine

Article Title: The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review

doi: 10.3390/jcm13185408

Figure Lengend Snippet: Studies investigating the potential antiarrhythmic effects of SGLT2is on AF recurrence.

Article Snippet: Zhou et al., 2022 [ ] , First Affiliated Hospital of Anhui Medical University (China) , Observational Retrospective Single-center Study , Patients with HF (n = 903), including 78 participants with AF and 825 participants without AF at baseline. , EMPA DAPA CANA , N/A , SGLT2i users experienced a lower prevalence of AF (8.4% vs. 12.1%, p < 0.001) and a lower risk of developing AF (OR 0.76, 95% CI: [0.70–0.85], p < 0.001) compared to non-SGLT2i users. The effect of SGLT2is on AF episodes was consistent irrespectively of age, gender, BMI, and eGFR..

Techniques: Control

Journal: Scientific Reports

Article Title: SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort

doi: 10.1038/s41598-021-89752-w

Figure Lengend Snippet: Demographics, clinical characteristics, and outcomes of type 2 diabetes mellitus patients on SGLT2i who developed EuDKA or hDKA.

Article Snippet: All patients with T2D using SGLT2i and admitted to the three hospitals of Weill Cornell Medicine affiliated-Hamad Medical Corporation, Qatar, with diabetic ketoacidosis between 2015 and 2020 were included in the study.

Techniques: Infection

Journal: Scientific Reports

Article Title: SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort

doi: 10.1038/s41598-021-89752-w

Figure Lengend Snippet: Demographics based on SGLT2i class.

Article Snippet: All patients with T2D using SGLT2i and admitted to the three hospitals of Weill Cornell Medicine affiliated-Hamad Medical Corporation, Qatar, with diabetic ketoacidosis between 2015 and 2020 were included in the study.

Techniques:

Journal: Scientific Reports

Article Title: SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort

doi: 10.1038/s41598-021-89752-w

Figure Lengend Snippet: Literature review of last 30 reported cases of EuDKA in type 2 diabetes mellitus patients on SGLT2i.

Article Snippet: All patients with T2D using SGLT2i and admitted to the three hospitals of Weill Cornell Medicine affiliated-Hamad Medical Corporation, Qatar, with diabetic ketoacidosis between 2015 and 2020 were included in the study.

Techniques: Infection

Journal: Cell metabolism

Article Title: Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis

doi: 10.1016/j.cmet.2013.04.001

Figure Lengend Snippet: Leukocytosis develops in response to hyperglycemia via expansion and proliferation of BM progenitor cells. Chow fed non-diabetic WT (C57BL/6J), STZ-diabetic and Akita-diabetic mice were treated with a SGLT2i (5mg/kg; ISIS) in the drinking water for 4 wks. Representative flow cytometry plots of blood leukocyte subsets from (A) STZ-diabetic and (B) Akita-diabetic mice.

Article Snippet: Unless specifically indicated all diabetic mice were treated with SGLT2i from ISIS Pharmaceuticals at a dose of 5 mg/kg/day in drinking water.

Techniques: Flow Cytometry

Journal: The Journal of Clinical Investigation

Article Title: Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes

doi: 10.1172/JCI92450

Figure Lengend Snippet: (A–F) SGLT2i studies: C57BL/6 mice were made diabetic with STZ, and blood glucose was lowered with the SGLT2i dapagliflozin (25 mg/kg/d) in the drinking water for 4 weeks. (A) Blood glucose levels. (B and C) Circulating reticulated platelets (B) and Kupffer cell IL-6 expression (C) were measured by flow cytometry. (D) Plasma TPO levels were quantified by ELISA. (E and F) BM progenitor cells (E) and megakaryocytes (F) were quantified by flow cytometry. n = 6 control and STZ+SGLT2i and n = 4 STZ. *P < 0.05 vs. all groups. (G–K) ABR-215757 studies: C57BL/6 mice were made diabetic with STZ and treated with ABR-215757 (10 mg/kg/d) or vehicle in the drinking water for 4 weeks. (G) Blood glucose levels. Circulating reticulated platelets (H) and Kupffer cell IL-6 expression (I) were measured by flow cytometry. The abundance (J) and proliferation (K) of MkPs in the BM were quantified by flow cytometry. n = 6 control and n = 9 STZ and STZ+ABR. *P < 0.05 vs. WT (G) and vs. all groups (H–K). All data are mean ± SEM. P values were obtained using 1-way ANOVA.

Article Snippet: Cooper has been on advisory boards of and received lecturer fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly in relation to SGLT2i’s.

Techniques: Expressing, Flow Cytometry, Enzyme-linked Immunosorbent Assay